Kensey Nash (KNSY), a medical-device company focused on regenerative medicine, agrees to be bought by Royal DSM (RDSMY.PK) for $38.50/share, more than a 30% premium to Kensey Nash's close yesterday. (PR)
Kensey Nash (KNSY +24%) jumps after saying it's reached a settlement with St. Jude Medical (STJ -0.6%), resolving its dispute regarding vascular closure device licenses and related claims. Under the deal, St. Jude will pay Kensey $39 million over several quarters.
RDSMY.PK - 100% Barchart technical buy signal - 7 new highs and up 18.04% in the last month - Relative strength Index 74.71% and risng
View all 0 replies
RDSMY vs. ETF Alternatives
DSM ? Bright Science. Brighter Living.? Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create...More